Emerging Relationship Between the Gut Microbiota and Neurodegenerative Disorders

Published: Jan. 1, 2024

Language: Английский

---

Inhibition of Epsilon Toxin-Producing Clostridium perfringens with a Juice-Based Probiotic Medical Food for Dietary Management of Multiple Sclerosis

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 13, 2024

Abstract Background Multiple sclerosis (MS) is the most common disabling neurological disease in young adults, with symptom onset generally occurring between ages of 20 and 40 years. Worldwide, there are 2.8 million people MS, United States, nearly 1 million. Currently, nine oral medications FDA-approved for each which has its own undesirable side effects. The root cause MS remains unknown, but epsilon toxin-producing C. perfringens implicated as trigger. Proving this trigger requires ability to eliminate bacteria or their toxic effect. As an element gut microbiome, may be managed through dietary interventions, no specific supplement medical food currently available purpose. Materials Methods aim vitro research project was develop a juice-based probiotic management multiple by inhibiting growth . For probiotics, we used proprietary blend five strains Bifidobacterium ten Lactobacillus (“Doctor’s Biome Signature Probiotic Blend”). excipient, organic green fruit vegetable juices. probiotics were added sterilized excipient at 60 billion colony-forming units per two fluid ounces, yielding (MF-MS). Two , ATCC 3626 (type B) 3631 D), target microorganisms. Results Over six days culture, control samples (RCM broth) showed drastic population both strains, while test (MF-MS) demonstrated complete inhibition Clostridium Conclusion We have developed patent-pending, that inhibits type B D perfringens, which, according recent published clinical findings, thought MS. To our knowledge, first study such effect been clearly demonstrated.

Language: Английский

---

Inhibition of Epsilon Toxin-Producing Clostridium perfringens with a JuiceBased Probiotic Medical Food for Dietary Management of Multiple Sclerosis

International Journal of Preventive Medicine and Care, Journal Year: 2024, Volume and Issue: 2(1), P. 01 - 12

Published: March 21, 2024

Background Multiple sclerosis (MS) is the most common disabling neurological disease in young adults, with symptom onset generally occurring between ages of 20 and 40 years. Worldwide, there are 2.8 million people MS, United States, nearly 1 million. Currently, nine oral medications FDA-approved for each which has its own undesirable side effects. The root cause MS remains unknown, but epsilon toxin-producing C. perfringens implicated as trigger. Proving this trigger requires ability to eliminate bacteria or their toxic effect. As an element gut microbiome, may be managed through dietary interventions, no specific supplement medical food currently available purpose. Materials Methods aim vitro research project was develop a juice-based probiotic management multiple by inhibiting growth perfringens. For probiotics, we used proprietary blend five strains Bifidobacterium ten Lactobacillus (“Doctor’s Biome Signature Probiotic Blend”). excipient, organic green fruit vegetable juices. probiotics were added sterilized excipient at 60 billion colony-forming units per two fluid ounces, yielding (MF-MS). Two perfringens, ATCC 3626 (type B) 3631 D), target microorganisms. Results Over six days culture, control samples (RCM broth) showed drastic population both strains, while test (MF-MS) demonstrated complete inhibition Closterium Conclusion We have developed patent-pending, that inhibits type B D Clostridium which, according recent published clinical findings, thought MS. To our knowledge, first study such effect been clearly

Language: Английский

---

New therapeutic avenues in multiple sclerosis: is there a place for gut microbiota-based treatments?

Pharmacological Research, Journal Year: 2024, Volume and Issue: 209, P. 107456 - 107456

Published: Oct. 9, 2024

The bidirectional interaction between the gut and central nervous system (CNS), so-called microbiota-brain axis, is reported to influence brain functions, thus having a potential impact on development or progression of several neurodegenerative disorders. Within this context, it has been documented that multiple sclerosis (MS), an autoimmune inflammatory, demyelinating, disease CNS, associated with gastrointestinal symptoms, including constipation, dysphagia, faecal incontinence. Moreover, some evidence suggests existence altered microbiota (GM) composition in MS patients respect healthy individuals, as well GM dysbiosis typical features, increased intestinal permeability, disruption blood-brain barrier integrity, chronic inflammation, T cells differentiation. Starting from these assumptions, possible involvement alteration pathogenesis seems likely, its restoration could represent supplemental beneficial strategy against disabling disease. In regard, present review will explore preventive approaches (including dietary interventions, administration probiotics, prebiotics, synbiotics, postbiotics, use transplantation) be pursued prophylaxis combination pharmacological treatments aim re-establishing proper GM, helping prevent manage by alleviating symptoms slowing down progression.

Language: Английский

---

The next frontier in multiple sclerosis therapies: Current advances and evolving targets.

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 985, P. 177080 - 177080

Published: Nov. 2, 2024

Language: Английский

---

The Multiple Sclerosis Gut Microbiome and Disease Activity: a Systematic Review

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 92, P. 106151 - 106151

Published: Nov. 8, 2024

Language: Английский

---

UNA REVISIÓN NARRATIVA DE LITERATURA SOBRE LA FISIOPATOLOGÍA DE LA ESCLEROSIS MÚLTIPLE

Revista Ibero-Americana de Humanidades, Ciências e Educação, Journal Year: 2023, Volume and Issue: 9(11), P. 1992 - 2001

Published: Dec. 8, 2023

A esclerose múltipla (EM) é uma doença complexa e multifatorial que afeta o sistema nervoso central, caracterizada por inflamação, desmielinização neurodegeneração. patogênese envolve a ativação de células imunes autorreativas, incluindo CD8+, CD4+ Th1 Th17, papel significativo das B, particularmente relacionadas ao vírus Epstein-Barr. Além disso, fatores ambientais como infecção EBV, deficiência vitamina D, obesidade tabagismo contribuem para EM. O estresse oxidativo, disfunção no metabolismo do ferro microbioma intestinal também desempenham papéis cruciais na fisiopatologia. diversidade nos subtipos da EM influencia prognóstico as decisões tratamento. Novas terapias, aquelas visam ferro, apresentam potencial promissor, alterando visão tradicional fornecendo esperança tratamento eficaz. Contudo, questões relação entre distúrbios neuropsiquiátricos estratégias terapêuticas precisam estudos mais aprofundados avançar entendimento manejo dessa incapacitante.

---